Clear sterile aqueous solution of Oxytocin PhEur equivalent to 10 i.u. per ml (0.18 mg/ml) for parenteral administration.
Chlorbutanol PhEur 5 mg/ml is included as a preservative.
Injections of Oxytocin-S will initiate strong regular and purposeful contractions of the uterine muscle especially in the later stages of pregnancy and post-partum. Oxytocin-S evokes the `let down' of milk although it has no action on the smooth muscles of the gut or urinary bladder nor is it effective in the treatment of diabetes insipidus. The absence of vasopressor and antidiuretic effects make Oxytocin-S particularly suitable for obstetric use (stimulation of parturition promotion of uterine involution and control of post-partum haemorrhage) and the treatment of agalactia.
Oxytocin-S is indicated for:
Oxytocin-S should normally be given by deep intramuscular injection. See table.
| Species | Dosage |
| Queen | 2–5 i.u. 0.2–0.5 ml |
| Bitch | 2–10 i.u. 0.2–1 ml |
| Ewe goat sow | 2–10 i.u. 0.2–1 ml |
| Mare | 10–40 i.u. 1–4 ml |
| Other indications | |
| Cow | 10–40 i.u. 1–4 ml Adjunct to mastitis treatment A single dose of up to 80 i.u. (8 ml) prior to stripping out before the first mastitis treatment followed by repeated doses of 20 i.u. (2 ml) prior to each stripping out 2 or 3 times daily while mastitis treatment continues. |
Where the intravenous route is used these doses should be reduced to one-quarter of the intramuscular dose and the injection given slowly at a dilution of 1 in 10 Water for Injections Ph Eur.
Where speed of onset is not a priority Oxytocin-S may be given by the subcutaneous route.
A low initial dosage is recommended by any route as repeat administration is permissible.
Large doses may be employed in post-parturient animals.
1. When Oxytocin-S is used as an aid to parturition cervical dilation must be confirmed prior to administration to prevent the risk of foetal death and possible uterine rupture.
2. Oxytocin-S is contra-indicated in any form of obstructive dystocia.
3. Excessive doses of the product may delay parturition by producing incoordinated uterine contractions which interfere with the progress of the foetus especially in multiple pregnancies.
4. The effects of daily dosages of 100 i.u. or more (to facilitate `stripping out' of infected quarters in the treatment of mastitis in cows) on the oestrous cycle have not been fully investigated and the cycle length may be altered.
5. Adrenaline at physiological levels markedly reduces effect of oxytocin on the uterus or mammary gland. For this reason the animal should not be frightened when complete oxytocin effect is desired to cause either milk `let-down' or uterine contractions.
Care should be taken to avoid accidental self-injection. Should self-injection occur medical advice should be sought immediately. Women particularly during lactation or the later stages of pregnancy should avoid handling the product as it could cause smooth muscle (e.g. uterine) contraction.
Nil.
For animal treatment only. Keep out of reach of children.
Store in a refrigerator between +2°C and +8°C. Store out of light.
Avoid the introduction of contamination during use.
Following withdrawal of the first dose use the product within 28 days. Should any apparent growth or discolouration occur the product should be discarded.
Unused product and containers should be disposed of in accordance with any guidance from an appropriate waste regulation authority (e.g in U.K. the local office of the Environment Agency or SEPA).
POM.
25 ml.
Do not use in late pregnancy unless the intention is to promote parturition.
Vm 01708/4314.